| Literature DB >> 30558723 |
Anteneh A Tesfaye1, Asfar S Azmi2, Philip A Philip3.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease that is mostly diagnosed late in the course of the illness. Unlike other cancers in which measurable successes have been achieved with traditional chemotherapy, targeted therapy, and, recently, immunotherapy, PDAC has proved to be poorly responsive to these treatments, with only marginal to modest incremental benefits using conventional cytotoxic therapy. There is, therefore, a great unmet need to develop better therapies based on improved understanding of biology and identification of predictive and prognostic biomarkers that would guide therapy. miRNAs are small noncoding RNAs that regulate the expression of some key genes by targeting their 3'-untranslated mRNA region. Aberrant expression of miRNAs has been linked to the development of various malignancies, including PDAC. A series of miRNAs have been identified as potential tools for early diagnosis, prediction of treatment response, and prognosis of patients with PDAC. In this review, we present a summary of the miRNAs that have been studied in PDAC in the context of disease biology.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30558723 PMCID: PMC6854437 DOI: 10.1016/j.ajpath.2018.10.005
Source DB: PubMed Journal: Am J Pathol ISSN: 0002-9440 Impact factor: 4.307